Walgreens Boots Alliance (WBA) Shows Resilience in Q2 with $37.1 B in Sales
In the latest quarterly financial disclosure, Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported a significant quarter amidst challenging retail landscapes, showing resilience and adaptability. The company achieved a 6.3 percent increase in sales, reaching $37.1 billion.
This growth, reflecting a 5.7 percent increase on a constant currency basis, was driven by sales enhancements across all segments, underscoring the diverse strength of WBA’s operations. However, the financial landscape was not without its challenges. The company faced a $13.2 billion operating loss, primarily due to a substantial $12.4 billion non-cash impairment charge related to VillageMD goodwill.
This stark contrast to the previous year’s operating income of $197 million underlines the volatile market conditions impacting the healthcare and retail sectors. Despite these hurdles, adjusted operating income stood at $900 million, a 26.5 percent decrease on a constant currency basis. This was partly due to lower sale-leaseback gains and softer U.S. retail performance, partially offset by an uptick in U.S. Healthcare segment profitability.
WBA Outperforms EPS Expectations with $1.20 Adjusted EPS
When juxtaposed with pre-set expectations, WBA’s performance presents a mixed bag. Analysts had projected earnings per share (EPS) of $0.82 and revenue of $35.9 billion for the quarter. WBA outperformed revenue expectations with its $37.1 billion in sales, indicating robust growth and operational success.
However, the adjusted EPS of $1.20, a 3.4 percent increase that surpasses expectations, is overshadowed by the substantial non-cash impairment charges, leading to a net loss of $5.9 billion for the quarter. This stark discrepancy underscores WBA’s challenges amid its growth trajectory and strategic realignments.
WBA Narrows Fiscal 2024 Adj. EPS Guidance to $3.20 to $3.35
Looking ahead, WBA narrows its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting the ongoing challenges in the U.S. retail environment and strategic portfolio adjustments.
This revised guidance stems from the early wind-down of the sale-leaseback program and lower earnings from share sales of its equity method investee, Cencora, counterbalanced by effective execution in pharmacy services and a favorable adjusted effective tax rate.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Back to 
